96976 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons; Interleukins [IL] IL-2
T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#302IL-2 MUTANT PROTEIN AND MEDICINE CONTAINING SAME
#303MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
#304MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, AND METHODS OF MAKING AND USING THE SAME
#305IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES
#306MODIFIED INTERLEUKIN-2 (IL-2) MOLECULE AND USE THEREOF
#307TGF-Beta Polypeptides
#308ENCAPSULATED RNA REPLICONS AND METHODS OF USE
#309VIRAL VECTOR ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND USES THEREOF IN TREATING METABOLIC DISEASES IN FELINES
#310Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant Proteins
#311T-cell modulatory multimeric polypeptides and methods of use thereof
#312Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
#313INTERLEUKIN-2 PROPROTEINS AND USES THEREOF
#314IL-2 ORTHOLOGS AND METHODS OF USE
#315Methods for modulating an immune response
#316ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF
#317BIFUNCTIONAL SUPERKINES AND USES THEREOF
#318METHOD OF TREATING OR AMELIORATING A PATHOGENIC INFECTION BY ADMINISTERING AN INTERLEUKIN-2/TGF-BETA RECEPTOR FUSION POLYPEPTIDE
#319COMPOSITION FOR ANTIVIRUS COMPRISING NATURAL KILLER CELL
#320VIRUSES ENGINEERED TO PROMOTE THANOTRANSMISSION AND THEIR USE IN TREATING CANCER
#321NOVEL RECOMBINANT VACCINIA VIRUS AND USE THEREOF
#322IMMUNOSTIMULATING IL-2 ANALOGS
#323CYTOKINE FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
#324MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
#325METHOD FOR TREATING A GD2 POSITIVE CANCER
#326GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF
#327INTERLEUKIN-2 MUTEINS AND USES THEREOF
#328ANTAGONISTIC PEPTIDE TARGETING IL-2, IL-9, AND IL-15 SIGNALING FOR THE TREATMENT OF CYTOKINERELEASE SYNDROME AND CYTOKINE STORM ASSOCIATED DISORDERS
#329METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS
#330IL-2R-BETA-GAMMA BINDING COMPOUNDS
#331IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof
#332COMPOSITIONS AND METHODS FOR SIMULTANEOUSLY MODULATING EXPRESSION OF GENES
#333IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS AND RELATED DOSING
#334Fusion Polypeptide and Polypeptide Dimer, and Use Thereof
#335FUSION PROTEIN INCLUDING IL15 PROTEIN, IL15 RECEPTOR ALPHA PROTEIN, FC DOMAIN, AND IL2 PROTEIN, AND USE THEREOF
#336MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
#337MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
#338NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF
#339CHIMERIC MYD88 RECEPTORS FOR REDIRECTING IMMUNOSUPPRESSIVE SIGNALING AND RELATED COMPOSITIONS AND METHODS
#340Antibodies and methods for making and using the same
#341COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
#342Immunoconjugates of Interlukin-2 Mutant Polypeptides with Antibodies
#343MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
#344METHOD FOR PREPARING UNIVERSAL IMMUNE CELLS AND USE THEREOF
#345CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
#346ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS
#347ENHANCED-AFFINITY ANTI-ECM NANOBODY-CYTOKINE FUSIONS AND THEIR APPLICATIONS
#348SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS
#349COMBINATION CYTOKINES FOR METHODS AND COMPOSITIONS FOR TREATING CANCER
#350T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
#351Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders
#352FC-EPSILON CAR
#353SEPARATION MOIETIES AND METHODS OF USE THEREOF
#354FUSION PROTEIN AND USE THEREOF
#355A FUSION PROTEON OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) AND INTERLEUKIN-2 (IL-2) AND APPLICATIONS THEREOF
#356ENCAPSULATED CELLS EXPRESSING IL-2 AND USES THEREOF
#357IL-2 MUTANT AND APPLICATION THEREOF
#358Interleukin-9 Signaling in Chimeric Antigen Receptor (CAR) Immune Cells
#359T lymphocyte and use thereof
#360COLLAGEN-TARGETED FUSION PROTEINS AND ANTIBODIES
#361T-cell modulatory multimeric polypeptides and methods of use thereof
#362FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF
#363Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
#364MULTIMERS FOR VIRAL STRAIN EVOLUTION
#365COMBINATION THERAPY COMPRISING ANTI-CD137 ANTIBODIES
#366IL-2 VARIANTS
#367HUMANIZED ACE2-FC FUSION PROTEIN FOR TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION
#368Masked IL-2-Fc fusion polypeptides
#369Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
#370TISSUE TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
#371PHARMACEUTICAL COMPOSITION FOR ENHANCING RADIOTHERAPY COMPRISING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN
#372VIRAL VECTORS EXPRESSING THERAPEUTIC PROTEINS SPECIFICALLY IN MYELOID CELLS AND MICROGLIA
#373Engineered T Cells
#374COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
#375T-cell modulatory multimeric polypeptides and methods of use thereof
#376SERUM ALBUMIN BINDING NANOBODY COMPOSITIONS AND METHODS FOR USING THE SAME
#377METHODS FOR IMPROVED DELIVERY OF THERAPEUTIC AGENTS
#378MODIFIED NATURAL KILLER CELLS AND METHODS OF USING THE SAME
#379IMMUNOSTIMULATORY MULTIMERIC BINDING MOLECULES
#380CYTOKINE COMBINATION
#381Conjugate comprising an IL-2 moiety
#382Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
#383RECOMBINANT VACCINIA VIRUS
#384MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
#385MULTIMERS, TETRAMERS & OCTAMERS
#386Modified TNF-α antibodies and uses thereof
#387Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
#388IL-2 SEQUENCES AND USES THEREOF
#389INTERLEUKIN-2 MUTANT AND USE THEREOF
#390Elimination of BCMA-positive malignancies by CAR expressing NK cells
#391PLASMID ENCODING B-CELL ACTIVATING FACTOR RECEPTOR (BAFF-R) AND USES OF SAME IN THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES IN FISH
#392GPC3 CAR- T CELLS SECRETING IL-18 AND METHODS OF MAKING AND USING THE SAME
#393MASKED IL-2 CYTOKINES AND THEIR CLEAVAGE PRODUCTS
#394INTERLEUKIN-2 MUTANT AND USE THEREOF
#395ANTIGEN-PRESENTING EXTRACELLULAR VESICLES, COMPOSITION CONTAINING SAME, AND METHOD FOR PRODUCTION THEREOF
#396FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN FRAGMENT OR VARIANT THEREOF, AND USES THEREOF
#397Methods of treating graft versus host disease using IL-2 muteins
#398Immunoconjugates
#399Modified T cells, pharmaceutical composition, manufacturing method thereof, and method of using the same
#400IMMUNOREGULATORY METHOD, NUCLEIC ACID COMPOSITION FOR IMMUNOREGULATION AND USE THEREOF
#401Immunostimulating IL-2 analogs
#402T-CELL MODULATORY MULTIMERIC POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF
#403Methods for modulating an immune response
#404NOVEL MASKED CYTOKINES AND METHODS OF USE THEREOF
#405METHODS FOR EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF
#406FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF
#407MULTIFUNCTIONAL MOLECULES THAT BIND TO CD33 AND USES THEREOF
#408ANAPLASTIC LYMPHOMA KINASE CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
#409CHIMERIC FUSIONS BETWEEN C4-BINDING PROTEIN C-TERMINAL SEGMENT AND ANGIOPOIETIN-1 FIBRINOGEN-LIKE DOMAIN AS ANGIOPOIETIN MIMETICS AND TIE2 AGONISTS TO TREAT VASCULAR DISEASES
#410IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
#411INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
#412Immunoconjugates
#413LIGAND-BINDING FUSION PROTEINS
#414Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
#415MODULATING GAMMA-C-CYTOKINE ACTIVITY
#416Recombinant Human Neuregulin Derivatives and Use Thereof
#417T-CELL MODULATORY CHIMERIC MOLECULES AND METHODS OF USE THEREOF
#418NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF
#419GENETICALLY MODIFIED NATURAL KILLER CELLS AND METHODS OF USE THEREOF
#420INTERLEUKIN-2 IN COMBINATION WITH TNF RECEPTOR FAMILY MEMBERS FOR THE EXPANSION OF T-REGULATORY CELLS
#421INTERLEUKIN 2 CHIMERIC CONSTRUCTS
#422Masked cytokine polypeptides
#423Masked cytokine polypeptides
#424CD122 WITH ALTERED ICD STAT SIGNALING
#425Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
#426PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF
#427Superagonists, partial agonists and antagonists of interleukin-2
#428ENGINEERED INTERLEUKIN-2 RECEPTOR BETA AGONISTS
#429Chimeric antigen receptors, compositions and applications thereof
#430ANTI-ICOS ANTIBODIES
#431IL2-BASED THERAPEUTICS AND METHODS OF USE THEREOF
#432Prame TCR Receptors And Uses Thereof
#433MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#434Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
#435Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
#436CHIMERIC CYTOKINE MODIFIED ANTIBODIES AND METHODS OF USE THEREOF
#437ANTI-ICOS ANTIBODIES
#438Dual cytokine fusion proteins comprising IL-10
#439Dual cytokine fusion proteins comprising IL-10
#440COMPOSITIONS AND METHODS FOR PROMOTING HEMATOPOIETIC CELL CYTOTOXICITY
#441METHODS AND MATERIALS FOR TARGETED EXPANSION OF IMMUNE EFFECTOR CELLS
#442TGF-β polypeptides
#443INTERLEUKIN-2 DERIVATIVE
#444IL2 agonists and methods of use thereof
#445T-cell modulatory multimeric polypeptides and methods of use thereof
#446IL2 Agonists
#447BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS
#448CAR NKTs Expressing Artificial Micro RNA-Embedded shRNA for Downregulation of MHC Class I & II Expression
#449Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
#450T-cell modulatory multimeric polypeptides and methods of use thereof
#451Dual cytokine fusion proteins comprising IL-10
#452CD25 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#453DESIGNED IL-2 VARIANTS
#454IL-2 COMPOSITIONS AND METHODS OF USE THEREOF
#455MODIFIED IL-2 PROTEINS, PEG CONJUGATES, AND USES THEREOF
#456Compositions and Uses for Engineered Therapeutic Microbes and Associated Receptors
#457Masked interleukin-12 polypeptides
#458CHIMERIC PROTEINS IN AUTOIMMUNITY
#459IL-2 FUSION PROTEINS THAT PREFERENTIALLY BIND IL-2RALPHA
#460NOVEL IL-21 PRODRUGS AND METHODS OF USE THEREOF
#461T-cell modulatory multimeric polypeptides and methods of use thereof
#462INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
#463Modified Interleukin 2 (IL-2) Polypeptides, Conjugates and Uses Thereof
#464MULTISPECIFIC AND MULTIFUNCTIONAL MOLECULES AND USES THEREOF
#465Primary NK CAR Constructs And Methods
#466T CELL RECEPTORS AND METHODS OF USE THEREOF
#467Dual cytokine fusion proteins comprising IL-10
#468Dual cytokine fusion proteins comprising IL-10
#469Dual cytokine fusion proteins comprising IL-10
#470IL-2 CYTOKINE PRODRUGS COMPRISING A CLEAVABLE LINKER
#471Fusion Protein And Composition For Treating Animal Tumors
#472Dual cytokine fusion proteins comprising IL-10
#473SYNTHETIC IMMUNE CELLS AND METHODS OF USE THEREOF
#474IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS
#475SPHINGOLIPIDS FOR GENERATING REGULATORY CD4+ T CELLS
#476Method of treating or ameliorating a pathogenic infection by administering an interleukin-2/TGF-β receptor fusion polypeptide
#477FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN BINDING MOLECULES FOR MODULATING IMMUNE CELL FUNCTION
#478Agents and Methods for Treating Viral Infections
#479IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLES
#480NOVEL IMMUNOCONJUGATES
#481METHODS AND MATERIALS FOR TARGETED EXPANSION OF REGULATORY T CELLS
#482MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN DIMER AND APPLICATION THEREOF
#483De novo design of potent and selective interleukin mimetics
#484NOVEL INTERLEUKIN-2 VARIANTS FOR THE TREATMENT OF CANCER
#485CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY
#486METHOD OF DIAGNOSING CANCER AND DIAGNOSIS KIT USING MEASUREMENT OF NK CELL ACTIVITY
#487IL-2 COMPOSITIONS AND METHODS OF USE THEREOF
#488IL-2 MUTANT PROTEIN PROLIFERATING IMMUNE CELLS
#489IL2 agonists and methods of use thereof
#490Separation moieties and methods of use thereof
#491NOVEL METHOD
#492IL-2 CHIMERIC PROTEINS FOR IMMUNOSUPPRESSION
#493Engineered IL-2 Fc fusion proteins
#494PROTEIN HETERODIMER AND USE THEREOF
#495PROTEIN MOLECULE AND USE THEREOF
#496METHODS OF PRODUCING AGGREGATE-FREE MONOMERIC DIPHTHERIA TOXIN FUSION PROTEINS AND THERAPEUTIC USES
#497Superagonists and antagonists of interleukin-2
#498IL-2 muteins and uses thereof
#499SYNERGISTIC TUMOR TREATMENT WITH IL-2 AND INTEGRIN-BINDING-FC FUSION PROTEIN
#500CELL SURFACE COUPLING OF NANOPARTICLES
#501IL-2 muteins and uses thereof
#502Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
#503Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells
#504T-cell modulatory multimeric polypeptides and methods of use thereof
#505Methods of using interleukin-2 agents
#506NOVEL INTERLEUKIN-2 VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF
#507Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells
#508Methods and compositions for natural killer cells
#509CYTOKINE-BASED IMMUNE CELLS AND IMMUNOTHERAPEUTIC USE THEREOF
#510T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#511Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
#512NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#513NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#514BISPECIFIC IMMUNOTOXINS TARGETING HUMAN CD25+CCR4+ TUMORS AND REGULATORY T-CELLS
#515Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
#516Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof
#517TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES
#518IMMUNOSTIMULATORY BACTERIA-BASED VACCINES, THERAPEUTICS, AND RNA DELIVERY PLATFORMS
#519METHODS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND USES THEREOF
#520MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
#521MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#522CHEMOKINE EXPRESSING CELL AND USE THEREOF
#523CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF
#524Methods for modulating an immune response
#525MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#526Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
#527Antibodies comprising a polypeptide inserted in framework 3 region
#528T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#529Recombinant poxviruses for cancer immunotherapy
#530Activatable interleukin-2 polypeptides and methods of use thereof
#531De novo design of potent and selective interleukin mimetics
#532HUMAN INTERLEUKIN-2 VARIANT OR DERIVATIVE THEREOF
#533Interleukin-2 polypeptide conjugates and their uses
#534SALMONELLA VACCINE FOR THE TREATMENT OF CORONAVIRUS
#535MATERIALS AND METHODS FOR PRODUCING BIOENGINEERED VIRUS SPECIFIC LYMPHOCYTES
#536RECOMBINANT VACCINIA VIRUS
#537METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND USE THEREOF
#538T-cell modulatory multimeric polypeptides and methods of use thereof
#539CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORS
#540NOVEL IMMUNOSUPPRESSIVE INTERLEUKIN 2
#541Fusion proteins with extended serum half life
#542Split interleukin mimetics and their use
#543Dual cytokine fusion proteins comprising IL-10
#544EXPOSED COLLAGEN-TARGETED FUSION CYTOKINE FOR IMMUNE MODULATION IN INVASIVE CANCERS AND LESIONS OF INFECTIONS
#545MASKED CYTOKINE POLYPEPTIDES
#546MULTIVALENT REGULATORY T CELL MODULATORS
#547Activatable interleukin-2 polypeptides and methods of use thereof
#548THERAPEUTIC COMPOUNDS AND METHODS
#549IL-2 FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
#550Protein heterodimer and use thereof
#551SPHINGOSINE KINASE 1 AND FUSION PROTEIN COMPRISING THE SAME AND USE THEREOF
#552Circular tandem repeat proteins
#553Novel Rationally Designed Protein Compositions
#554QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR FOR STABLE GENETIC MODIFICATION OF CELLULAR IMMUNOTHERAPIES
#555GENERATING HPV ANTIGEN-SPECIFIC T CELLS FROM A NAÏVE T CELL POPULATION
#556Anti-PD-L1 antibodies
#557IL-2 FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
#558Fc-epsilon car
#559DECOY POLYPEPTIDES
#560Conjugates of an IL-2 moiety and a polymer
#561Activatable IL2 composition and methods of use
#562Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
#563Human interleukin-2 conjugates biased for the interleukin-2 receptor beta GAMMAc dimer and conjugated to a nonpeptidic, water-soluble polymer
#564IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
#565STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY
#566IL-15 Variants and Uses Thereof
#567ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS
#568Modular synthetic receptors and methods of use
#569Enhanced antigen presenting ability of RNA car T cells by co-introduction of costimulatory molecules
#570ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS
#571IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
#572Treatment of Acute Respiratory Distress Syndrome by T Regulatory Cells
#573THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS
#574Immunotherapeutic tumor treatment method
#575IL2 Agonists
#576HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#577Compositions and methods for targeted cytokine delivery
#578GENERATING VIRUS OR OTHER ANTIGEN-SPECIFIC T CELLS FROM A NAÏVE T CELL POPULATION
#579TARGETED IMMUNOTOLERANCE
#580Biomolecule Coated Particles and Films and Uses Thereof
#581Cell surface coupling of nanoparticles
#582Partial agonists of interleukin-2
#583INTERLEUKIN-2 VARIANTS AND METHODS OF USES THEREOF
#584Tissue targeted immunotolerance with a CD39 effector
#585Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
#586NOVEL CYTOKINE PRODRUGS
#587Pharmaceutical Composition Containing Fusion Protein and Use Thereof
#588Engineered safety in cell therapy
#589Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
#590Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
#591Interleukin-2 fusion proteins and uses thereof
#592USES AND METHODS FOR ONCOLYTIC VIRUS TARGETING OF IL-4/IL-13 AND FUSIONS THEREOF
#593Fusion proteins composed of an interleukin-2 mutein and type I interferon
#594Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
#595IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2
#596MASKED CYTOKINE CONJUGATES
#597Interleukin-2 and use thereof
#598Immunostimulating vector system
#599IMMUNE CHECKPOINT THERAPY
#600IL-13/IL-4 SUPERKINES: IMMUNE CELL TARGETING CONSTRUCTS AND METHODS OF USE THEREOF